Verizon, Anheuser-Busch and Gilead Sciences are making headlines this morning before the opening bell. » Read More
The "Fast Money" traders get into biotech and give you 5 trades in a mixed sector.
U.S. stocks closed lower as health care stocks weighed, but the major averages pared losses significantly for the Dow and S&P to post monthly gains.
Mark Spellman, Co-Portfolio Manager at Alpine Funds, talks about some of the companies that have recently raised their dividends.
Some of the names on the move ahead of the open.
Check out the companies making headlines after the bell: Amazon, LinkedIn, Gilead Sciences, Pandora and more.
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
CNBC's Meg Tirrell reports Gilead Sciences' quarterly results.
Options trader Dan Nathan says the biotech sector could get a boost on earnings.
The pharmacy benefits manager is looking to partner with retail pharmacies that do the best job at keeping diabetes patients healthy.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including two positive calls on L Brands, and Raymond James reiterating its outperform on Bloomin' Brands.
Sustainable investing is up 60 percent in the past year, BlackRock estimates.
Is it time to buy biotech as the sector is breaking out?
The "Fast Money" traders give you 4 names to buy in biotech on new inversion rule.
Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.
CNBC's Dom Chu looks at stocks that were among the biggest losers in the first quarter.
As the first quarter comes to a close, one sector notably stands out in the negative column: biotech.
The "Fast Money" traders give their final trades and get ready for the final day of the quarter.
The Fast Money traders share their final trades of the day.
U.S. stocks closed mixed Monday as investors eyed oil prices and awaited data and comments from key Fed policymakers due later in the week.
A federal jury has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.